Natural Products Synthesis

DOI: 10.1002/ange.201006230

Convergent Total Synthesis of (+)-TMC-151C by a Vinylogous Mukaiyama Aldol Reaction and Ring-Closing Metathesis**

*Ryosuke Matsui, Kentaro Seto, Yuna Sato, Takahiro Suzuki, Atsuo Nakazaki, and Susumu Kobayashi**

Antibiotic agents of the TMC-151 family were originally isolated from the fungus *Gliocladium catenulatum* Gilman & Abbott TC 1280 by a research group at the pharmaceutical company Tanabe Seiyaku in 1999 as novel polyketides containing β-D-mannoside and D-mannitol groups.[1] A related TMC-171 family of antibiotics and TMC-154 were also isolated.[2] Of these compounds, TMC-151C (**1**) shows the most significant cytotoxicity against a wide range of tumor cell lines, including HCT-116, B16, and HeLa cells. TMC-151C displays several interesting structural features. Notably, 1) the polyketide moiety contains three contiguous *anti* homoallylic alcohol motifs in the C1–C13 segment and three methyl-substituted asymmetric carbon centers in the C14–C20 segment, and 2) D-mannose is attached to the C13 hydroxy group as β-D-mannoside, which is still problematic in terms of chemical synthesis (Scheme 1). This combination of significant biological activity and structural complexity encouraged us to attempt the total synthesis of (+)-TMC-151C (**1**).



Scheme 1. Structure of (+)-TMC-151C and the vinylogous Mukaiyama aldol reaction (VMAR). TMC-151C contains three units that should be amenable to synthesis by the VMAR: C2–C5, C6–C9, and C10–C13. TBS = *tert*-butyldimethylsilyl.

We previously developed a highly stereoselective vinylogous Mukaiyama aldol reaction (VMAR) that enabled remarkable remote asymmetric induction by using the vinylketene silyl N,O-acetals **2** and **3** (Scheme 1).[3] From a synthetic point of view, this method can directly afford the *anti*-δ-hydroxy-α,γ-dimethyl α,β-unsaturated carbonyl unit which is present in many naturally occurring compounds. Indeed, the VMAR has been utilized successfully in natural product syntheses by many research groups,[4] including our own.[5] Given the presence of three *anti* homoallylic alcohol motifs (C2–C5, C6–C9, and C10–C13 units) in (+)-**1**, we reasoned that the total synthesis of **1** would provide a representative example of the VMAR. Herein, we report the first total synthesis of (+)-TMC-151C (**1**).

We initially attempted a straightforward linear approach consisting of three iterative VMARs (Scheme 2). The carbohydrate units would then be combined at a later stage in the synthesis. According to the established protocol, the first VMAR of the known chiral aldehyde **4**[6] with the vinylketene silyl N,O-acetal **3** in the presence of $TiCl_4$ afforded the



Scheme 2. Attempted linear approach: a) $TiCl_4$ (1.0 equiv), aldehyde **4** (1.5 equiv), CH_2Cl_2, −78→−40 °C, 91% (d.r. > 20:1); b) TESOTf, 2,6-lutidine, CH_2Cl_2, 0 °C, quantitative; c) $LiBH_4$, MeOH, Et_2O, 0 °C, 98%; d) MnO_2, CH_2Cl_2, room temperature, 99%; e) $TiCl_4$ (4.0 equiv), **3** (5.0 equiv), CH_2Cl_2, −78→−20 °C, 51% (d.r. 13:1); f) TESOTf, 2,6-lutidine, CH_2Cl_2, 0 °C, 93%; g) $LiBH_4$, MeOH, Et_2O, 0 °C, 94%; h) MnO_2, CH_2Cl_2, room temperature, quantitative; i) $TiCl_4$ (5.0 equiv), **3** (5.0 equiv), CH_2Cl_2, −78→−20 °C, complex mixture. TES = triethylsilyl, Tf = trifluoromethanesulfonyl.

[*] R. Matsui, K. Seto, Y. Sato, Dr. T. Suzuki, Dr. A. Nakazaki, Prof. Dr. S. Kobayashi
Faculty of Pharmaceutical Sciences, Tokyo University of Science
2641 Yamazaki, Noda-shi, Chiba 278-8510 (Japan)
Fax: (+81) 4-7121-3671
E-mail: kobayash@rs.noda.tus.ac.jp
Homepage: http://www.rs.noda.tus.ac.jp/kobalab/index.html

[**] This research was supported in part by a Grant-in-Aid for Scientific Research (B; KAKENHI No.18390010) from the Japan Society for the Promotion of Science.

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/anie.201006230.

corresponding C12–C13 *anti* aldol adduct **5** in 91% yield with high diastereoselectivity. TES protection of the secondary alcohol, reductive removal of the chiral auxiliary with $LiBH_4$, and oxidation of the resulting primary alcohol with MnO_2 provided the second VMAR substrate **6**. An excess amount of $TiCl_4$ and the N,O-acetal **3** were required for this second VMAR owing to the low reactivity of enal **6**. Under these conditions, the desired aldol adduct **7** was formed in 51% yield with good diastereoselectivity (d.r. 13:1; the minor diastereomer was could be separated from **7** by preparative TLC). The aldol adduct **7** was transformed into enal **8** by the same sequence of reactions used for the conversion of **5** into **6**. However, despite repeated efforts, the desired third VMAR product **9** could not be obtained from **8**. In each case, a complex mixture of products was generated, probably as a result of the Lewis acidity of $TiCl_4$.

The lack of success with the third VMAR in the linear approach prompted us to investigate an alternative synthetic route. In this context, we recently developed an unusually *E*-selective silicon-tethered ring-closing metathesis (RCM) of silylene acetal **10**, prepared from an allylic alcohol and a homoallylic alcohol (Scheme 3).[7] Our novel convergent strategy, which is based on this methodology, is outlined in Scheme 4. (+)-TMC-151C (**1**) was divided at the C6–C7 olefin into two fragments: the left-hand fragment **12** and the right-hand fragment **13**. We envisaged that **12** and **13** could be connected by using this *E*-selective silicon-tethered RCM methodology. We reasoned that the use of this methodology could result in a short and convergent synthetic route. The left-hand fragment **12** was synthesized from the VMAR product **5** by β-mannosylation followed by asymmetric crotylation. To dispense with the protection–deprotection steps, we introduced a β-mannosyl group into **5**. Although β-mannoside formation is often regarded as one of the most difficult glycosylation reactions, several excellent methodologies have been developed to facilitate this transformation.[8] The right-hand fragment **13** was synthesized by a VMAR with methacrolein (**14**) and esterification with a D-mannitol derivative.



Scheme 4. Convergent retrosynthetic analysis based on the VMAR and RCM.



Scheme 3. Formation of an eight-membered ring by *E*-selective silicon-tethered ring-closing metathesis (RCM).

The synthesis of the left-hand fragment **12** began with a β-selective mannosylation of **5** (Scheme 5). After extensive studies in which we examined a variety of different approaches, we found that β-mannosylation of **5** with the mannosyl donor **15** by the method developed recently by Crich and Karatholuvhu[8g] afforded the desired product **16** in 82% yield almost as a single isomer. The stereostructure of **16** was determined by NOE experiments.[9] Reductive removal of the chiral auxiliary in **16** with $LiBH_4$, followed by the



Scheme 5. Synthesis of the left-hand fragment **12**: a) **15** (Ar = *p*-$CF_3C_6H_4$), BSP, Tf_2O, TTBP, 4Å M.S., CH_2Cl_2, −60 °C, 82% (β:α > 20:1); b) $LiBH_4$, MeOH, Et_2O, 0 °C, 97%; c) Na, liquid NH_3, THF–*t*BuOH, −70 → −20 °C, 75%; d) TESOTf, 2,6-lutidine, CH_2Cl_2, −78 °C, quantitative; e) AcOH–H_2O, THF, room temperature, 47% (89% based on recovered starting material); f) MnO_2, CH_2Cl_2, room temperature, 97%; g) (*E*)-(*R*,*R*)-crotyl boronate, 4Å M.S., toluene, −78 °C, 89% (d.r. 4.7:1). Bn = benzyl, BSP = 1-benzenesulfinylpiperidine, M.S. = molecular sieves, TTBP = 2,4,6-tri-*tert*-butylpyrimidine.

removal of all protecting groups under Birch conditions,[8g] provided the pentaol **17**. Following the protection of all five hydroxy groups of **17** as their TES ethers, selective cleavage of the primary allylic TES ether with AcOH–H_2O–THF afforded the corresponding allylic alcohol, which was oxidized with MnO_2 in 97% yield. A Roush asymmetric *anti* crotylation[10] then gave the desired left-hand fragment **12** in 89% yield with d.r. 4.7:1 (the minor diastereomer was separated by silica-gel column chromatography).

Next, we focused on the synthesis of the right-hand fragment **13** (Scheme 6). The synthesis commenced with a VMAR between the N,O-acetal **3** and methacrolein (**14**). Under standard conditions ($TiCl_4$ in CH_2Cl_2, 2.0 equivalents of **14**), the aldol adduct **18** was formed in low yield (23%), presumably as a result of polymerization of **14**. During an extensive survey of reaction conditions, we improved the yield of



Scheme 7. Completion of the total synthesis of (+)-TMC-151C (**1**): a) **13** (1.5 equiv), Et_2NPh_2SiCl, Et_3N, DMAP (cat.), then **12**, DMAP, CH_2Cl_2, 0°C→RT, 54% (81% from **12** on the basis of recovered starting material); b) Hoveyda–Grubbs second-generation catalyst (20 mol%), *p*-benzoquinone, xylene, reflux, 87% (*E*/*Z* > 20:1); c) HF–pyridine, pyridine, then aqueous HF, THF–MeCN, 0°C→RT, 54%.



Scheme 6. Synthesis of the right-hand fragment **13**: a) $TiCl_4$, methacrolein (**14**; 4.0 equiv), toluene, −78→−50°C, 65% (d.r. > 20:1); b) PMBOC(NH)CCl_3, CSA (cat.), CH_2Cl_2, 0°C→RT, 68%; c) LiOH·H_2O, H_2O_2, THF–H_2O, 0°C, 83%; d) Piv_2O, Et_3N, CH_2Cl_2, 0°C; e) **20**, DMAP, toluene, room temperature, 60% (over 2 steps); f) DDQ, CH_2Cl_2–buffer (pH 7.5), 0°C, 93%. PMB = *p*-methoxybenzyl, CSA = camphorsulfonic acid, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, DMAP = *N*,*N*-4-dimethylaminopyridine, Piv = pivaloyl.

18 to 65% with greater than 20:1 diastereoselectivity by using toluene as the solvent and 4.0 equivalents of **14**. The major by-products were
1,4-addition adducts (15% yield) as a mixture of diastereomers. After protection of the secondary alcohol with PMBOC(NH)CCl_3, the chiral auxiliary was removed with LiOH and H_2O_2 to provide the carboxylic acid **19**. Esterification of the unsaturated acid **19** (as the mixed anhydride formed by treatment with Piv_2O) with the alcohol **20**[9] afforded the corresponding ester in 60% overall yield for the two steps. Cleavage of the PMB ether gave the right-hand fragment **13**.

With both fragments in hand, we proceeded to the final stage of the total synthesis of (+)-**1** (Scheme 7). Our silicon-tethering method with Et_2NPh_2SiCl/Et_3N/DMAP[7] was used successfully for the connection of **12** and **13** to afford silylene acetal **21** in 54% yield (81% from **12** as calculated on the basis of recovered starting material). The crucial silicon-tethered RCM[11,12] of **21** under the previously reported conditions[7] (with the Hoveyda–Grubbs second-generation catalyst[13] in the presence of *p*-benzoquinone[14] in xylene at reflux) provided the desired *E* olefin **22** in 87% yield with high stereoselectivity (*E*/*Z* > 20:1). The configuration of the *E* olefin **22** was determined by NOE experiments.[9] Finally, desilylation by the sequential treatment of **22** with HF·pyridine and aqueous HF completed the total synthesis of (+)-TMC-151C.[15] The spectroscopic data (^{1}H NMR, ^{13}C NMR, and IR spectra, HRMS) of synthetic (+)-**1** were identical to those of natural (+)-**1**.[1a]

In conclusion, we have completed the first total synthesis of (+)-TMC-151C by a highly convergent synthetic route. Characteristic features of the present synthesis include the construction of the C1–C5 and C9–C13 units by vinylogous Mukaiyama aldol reactions and the use of a silicon-tethered diene for the stereoselective formation of the C6–C7 double bond by our recently developed *E*-selective RCM reaction to give an eight-membered ring. This synthetic strategy should provide efficient access to a range of related naturally occurring polyketides containing pent-2-ene-1,5-diol units.

Received: October 5, 2010
Published online: December 22, 2010

Keywords: aldol reaction · natural products · polyketides · ring-closing metathesis · total synthesis

[1] a) J. Kohno, M. Nishio, M. Sakurai, K. Kawano, H. Hiramatsu, N. Kameda, N. Kishi, T. Yamashita, T. Okuda, S. Komatsubara, *Tetrahedron* **1999**, *55*, 7771–7786; b) J. Kohno, M. Nishio, N. Kishi, T. Okuda, S. Komatsubara, *J. Antibiot.* **2000**, *53*, 1301–1304; c) T. Okuda, J. Kohno, N. Kishi, Y. Asai, M. Nishio, S. Komatsubara, *Mycoscience* **2000**, *41*, 239–253.

[2] J. Kohno, Y. Asai, M. Nishio, M. Sakurai, K. Kawano, H. Hiramatsu, N. Kameda, N. Kishi, T. Okuda, S. Komatsubara, *J. Antibiot.* **1999**, *52*, 1114–1123.

[3] a) S.-i. Shirokawa, M. Kamiyama, T. Nakamura, M. Okada, A. Nakazaki, S. Hosokawa, S. Kobayashi, *J. Am. Chem. Soc.* **2004**, *126*, 13604 – 13605; b) M. Shinoyama, S.-i. Shirokawa, A. Nakazaki, S. Kobayashi, *Org. Lett.* **2009**, *11*, 1277 – 1280; c) M. Yamaoka, A. Nakazaki, S. Kobayashi, *Tetrahedron Lett.* **2010**, *51*, 287 – 289.

[4] a) S. Hosokawa, T. Ogura, H. Togashi, K. Tatsuta, *Tetrahedron Lett.* **2005**, *46*, 333 – 337; b) S. Hosokawa, K. Yokota, K. Imamura, Y. Suzuki, M. Kawarasaki, K. Tatsuta, *Tetrahedron Lett.* **2006**, *47*, 5415 – 5418; c) S. Hosokawa, S. Kuroda, K. Imamura, K. Tasuta, *Tetrahedron Lett.* **2006**, *47*, 6183 – 6186; d) X. Jiang, B. Liu, S. Lebreton, J. K. De Brabander, *J. Am. Chem. Soc.* **2007**, *129*, 6386 – 6387; e) K. C. Nicolaou, R. Guduru, Y.-P. Sun, B. Banerji, D. Y.-K. Chen, *Angew. Chem.* **2007**, *119*, 6000 – 6004; *Angew. Chem. Int. Ed.* **2007**, *46*, 5896 – 5900; f) K. C. Nicolaou, Y.-P. Sun, R. Guduru, B. Banerji, D. Y.-K. Chen, *J. Am. Chem. Soc.* **2008**, *130*, 3633 – 3644; g) A. Schmauder, S. Müller, M. E. Maier, *Tetrahedron* **2008**, *64*, 6263 – 6269; h) S. Hosokawa, K. Yokota, K. Imamura, Y. Suzuki, M. Kawarasaki, K. Tatsuta, *Asian J. Chem.* **2008**, *3*, 1415 – 1421; i) B. H. Lipshutz, B. Amorelli, *J. Am. Chem. Soc.* **2009**, *131*, 1396 – 1397; j) L. Wang, J. Gong, L. Deng, Z. Xiang, Z. Chen, Y. Wang, J. Chen, Z. Yang, *Org. Lett.* **2009**, *11*, 1809 – 1812; k) S. Hosokawa, Y. Mukaeda, R. Kawahara, K. Tatsuta, *Tetrahedron Lett.* **2009**, *50*, 6701 – 6704; l) S. Hosokawa, K. Matsushita, S. Tokimatsu, T. Toriumi, Y. Suzuki, K. Tatsuta, *Tetrahedron Lett.* **2010**, *51*, 5532 – 5536; for reviews, see: m) K. Tatsuta, S. Hosokawa, *Chem. Rev.* **2005**, *105*, 4707 – 4729; n) K. Tatsuta, S. Hosokawa, *Chem. Rec.* **2006**, *6*, 217 – 233; o) S. Hosokawa, K. Tatsuta, *Mini-Rev. Org. Chem.* **2008**, *5*, 1 – 18.

[5] a) T. Nakamura, S.-i. Shirokawa, S. Hosokawa, A. Nakazaki, S. Kobayashi, *Org. Lett.* **2006**, *8*, 677 – 679; b) S.-i. Shirokawa, M. Shinoyama, I. Ooi, S. Hosokawa, A. Nakazaki, S. Kobayashi, *Org. Lett.* **2007**, *9*, 849 – 852; c) M. Yamaoka, Y. Fukatsu, A. Nakazaki, S. Kobayashi, *Tetrahedron Lett.* **2009**, *50*, 3849 – 3852; d) M. Yamaoka, A. Nakazaki, S. Kobayashi, *Tetrahedron Lett.* **2009**, *50*, 6764 – 6768.

[6] E.-i. Negishi, Z. Tan, B. Liang, T. Novak, *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 5782 – 5787.

[7] R. Matsui, K. Seto, K. Fujita, T. Suzuki, A. Nakazaki, S. Kobayashi, *Angew. Chem.* **2010**, DOI: 10.1002/ange.201004746; *Angew. Chem. Int. Ed.* **2010**, DOI: 10.1002/anie.201004746.

[8] For examples of β-mannosylation, see: a) Y. Ito, T. Ogawa, *Angew. Chem.* **1994**, *106*, 1843 – 1845; *Angew. Chem. Int. Ed. Engl.* **1994**, *33*, 1765 – 1767; b) Y. Ito, H. Ando, M. Wada, T. Kawai, Y. Ohnishi, Y. Nakahara, *Tetrahedron* **2001**, *57*, 4123 – 4132; c) A. A.-H. Abdel-Rahman, S. Jonke, E. S. H. El Ashry, R. R. Schmidt, *Angew. Chem.* **2002**, *114*, 3100 – 3103; *Angew. Chem. Int. Ed.* **2002**, *41*, 2972 – 2974; d) S.-i. Tanaka, M. Takashina, H. Tokimoto, Y. Fujimoto, K. Tanaka, K. Fukase, *Synlett* **2005**, 2325 – 2328; e) D. Crich, P. Jayalath, *Org. Lett.* **2005**, *7*, 2277 – 2280; f) D. Crich, P. Jayalath, T. K. Hutton, *J. Org. Chem.* **2006**, *71*, 3064 – 3070; g) D. Crich, M. S. Karatholuvhu, *J. Org. Chem.* **2008**, *73*, 5173 – 5176; for a review, see: h) J. J. Gridley, H. M. I. Osborn, *J. Chem. Soc. Perkin Trans. 1* **2000**, 1471 – 1491.

[9] See the Supporting Information for details.

[10] a) W. R. Roush, K. Ando, D. B. Powers, A. D. Palkowitz, R. L. Halterman, *J. Am. Chem. Soc.* **1990**, *112*, 6339 – 6348; b) W. R. Roush, A. D. Palkowitz, K. Ando, *J. Am. Chem. Soc.* **1990**, *112*, 6348 – 6359.

[11] For reviews on olefin metathesis, see: a) A. K. Chatterjee, T.-L. Choi, D. P. Sanders, R. H. Grubbs, *J. Am. Chem. Soc.* **2003**, *125*, 11360 – 11370; b) S. J. Connon, S. Blechert, *Angew. Chem.* **2003**, *115*, 1944 – 1968; *Angew. Chem. Int. Ed.* **2003**, *42*, 1900 – 1923; c) A. Gradillas, J. Pérez-Castells, *Angew. Chem.* **2006**, *118*, 6232 – 6247; *Angew. Chem. Int. Ed.* **2006**, *45*, 6086 – 6101; d) J. Cossy, S. Arseniyadis, C. Meyer, R. H. Grubbs, *Metathesis in Natural Product Synthesis: Strategies, Substrates and Catalysts*, Wiley-VCH, Weinheim, **2010**.

[12] For previous examples of silicon-tethered ring-closing metathesis, see: a) P. A. Evans, V. S. Murthy, *J. Org. Chem.* **1998**, *63*, 6768 – 6769; b) T. R. Hoye, M. A. Promo, *Tetrahedron Lett.* **1999**, *40*, 1429 – 1432; c) A. Briot, M. Bujard, V. Gouverneur, S. P. Nolan, C. Mioskowski, *Org. Lett.* **2000**, *2*, 1517 – 1519; d) T. M. Gierasch, M. Chytil, M. T. Didiuk, J. Y. Park, J. J. Urban, S. P. Nolan, G. L. Verdine, *Org. Lett.* **2000**, *2*, 3999 – 4002; e) B. A. Harrison, G. L. Verdine, *Org. Lett.* **2001**, *2*, 2157 – 2159; f) P. Van de Weghe, D. Aoun, J.-G. Boiteau, J. Eustache, *Org. Lett.* **2002**, *4*, 4105 – 4108; g) P. A. Evans, J. Cui, G. P. Buffone, *Angew. Chem.* **2003**, *115*, 1776 – 1779; *Angew. Chem. Int. Ed.* **2003**, *42*, 1734 – 1737; h) E. M. Casey, P. Teesdale-Spittle, J. E. Harvey, *Tetrahedron Lett.* **2008**, *49*, 7021 – 7023; i) T. R. Hoye, J. Jeon, L. C. Kopel, T. D. Ryba, M. A. Tennakoon, Y. Wang, *Angew. Chem.* **2010**, *122*, 6287 – 6291; *Angew. Chem. Int. Ed.* **2010**, *49*, 6151 – 6155; for reviews on the use of silicon tethers, see: j) M. Bols, *Chem. Rev.* **1995**, *95*, 1253 – 1277; k) I. Fleming, A. Barbero, D. Walter, *Chem. Rev.* **1997**, *97*, 2063 – 2192; l) D. R. Gauthier, Jr., K. S. Zandi, K. J. Shea, *Tetrahedron* **1998**, *54*, 2289 – 2338; for more-recent examples of useful silicon tethering, see: m) M. Petit, G. Chouraqui, C. Aubert, M. Malacria, *Org. Lett.* **2003**, *5*, 2037 – 2040; n) J. B. Grimm, D. Lee, *J. Org. Chem.* **2004**, *69*, 8967 – 8970; o) J. Beignet, P. J. Jervis, L. R. Cox, *J. Org. Chem.* **2008**, *73*, 5462 – 5475.

[13] a) S. B. Garber, J. S. Kingsbury, B. L. Gray, A. H. Hoveyda, *J. Am. Chem. Soc.* **2000**, *122*, 8168 – 8179; b) S. Gessler, S. Randl, S. Blechert, *Tetrahedron Lett.* **2000**, *41*, 9973 – 9976.

[14] Isomerization of the terminal alkenes occurred to some extent during RCM without *p*-benzoquinone; for the effect of *p*-benzoquinone, see also: a) S. H. Hong, D. P. Sanders, C. W. Lee, R. H. Grubbs, *J. Am. Chem. Soc.* **2005**, *127*, 17160 – 17161; b) I. Larrosa, M. I. Da Silva, P. M. Gómez, P. Hannen, E. Ko, S. R. Lenger, S. R. Linke, A. J. P. White, D. Wilton, A. G. M. Barrett, *J. Am. Chem. Soc.* **2006**, *128*, 14042 – 14043.

[15] Although the $[\alpha]_D$ value of synthetic (+)-**1** ($+4.4\ \mathrm{deg\,cm^3\,g^{-1}\,dm^{-1}}$, $c = 1.3 \times 10^{-3}\ \mathrm{g\,cm^{-3}}$ in MeOH) was lower than that of natural (+)-**1** ($+27\ \mathrm{deg\,cm^3\,g^{-1}\,dm^{-1}}$, $c = 1.0 \times 10^{-3}\ \mathrm{g\,cm^{-3}}$ in MeOH), the stereostructure and the purity of synthetic (+)-**1** were confirmed by NMR spectroscopy.

